Infliximab is one of the most widely used tumour necrosis factor-alpha (TNF) inhibitors for control of Crohn disease. We report the case of a patient with ileocolonic Crohn disease developing major arterial thrombosis after treatment with infliximab. After conservative management and infliximab withdrawal, thrombus dissolution and vessel recannalisation were observed. Few cases of arterial thro...

some dermatologic manifestations are common in ulcerative colitis (uc). herein, we present a 36-year-old woman with ulcerative colitis and uncommon nasal mucosa pyoderma vegetans. the patient presented to our hospital with symptoms of active colitis and a concomitant 3×4×5 cm dermato-mucosal lesion in her left nasal lumen. after surgery of the mucosal lesion, the treatment for her active coliti...

OBJECTIVES Infliximab is the first anti-TNFalpha accepted by the Food and Drug Administration for use in inflammatory bowel disease treatment. Few clinical, biological and genetic factors tend to predict response in Crohn's disease (CD) patient subcategories, none widely predicting response to infliximab. DESIGN AND METHODS Twenty CD patients showing clinical response or non response to infli...

Infliximab is a monoclonal antibody against tumor necrosis factor (TNF) which has become an established therapy for Crohn's disease over the last 10 years. Given the similarities between Crohn's disease and ulcerative colitis (UC), it is no surprise that gastroenterologists have used infliximab in patients with UC who have failed other therapies. Although the initial controlled trials with infl...

AIM: Infliximab, an anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, has been reported to be effective in refractory uveoretinitis in Behçet's disease. Because it has been used clinically for a short time, information on its adverse effects is limited. We report a patient who developed cystoid macular edema (CME) following infliximab use for uveoretinitis associated with Behçet's dis...

Acute graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT). It has been proposed that tumor necrosis factor alpha (TNF-alpha) blockade with infliximab may be an effective treatment for severe (grades III-IV) GVHD. We determined if infliximab use in this high-risk population was associated with an additional increased risk of non-...

Objective. To follow-up on all available infliximab-treated SLE patients for safety and long-term efficacy in order to extract information that is useful for planning appropriate controlled trials with infliximab in SLE. Methods. We analysed charts of six patients treated in an open-label safety trial and seven additional patients treated with infliximab on a compassionate care basis for uncont...

UNLABELLED BACKGROUND To obtain detailed real-life data on costs and dosing patterns in the utilisation of the TNF inhibitors adalimumab, etanercept, and infliximab in patients treated in Switzerland. METHODS Administrative claims processed by a major Swiss health insurer between 2005 and 2008 were analysed. Patients with inflammatory rheumatic diseases (IRDs) with at least one prescriptio...

BACKGROUND & AIMS The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for ulcerative colitis (UC) have not been evaluated previously. METHODS This randomized, double-blind trial evaluated the efficacy and safety of 16 weeks of treatment with infliximab monotherapy, azathioprine monotherapy, or the 2 drugs combined in tumor necrosis factor-a antag...

BACKGROUND Pyoderma gangrenosum (PG) is a chronic ulcerating skin condition that often occurs in association with inflammatory bowel disease. There have been a number of reports of PG responding to infliximab, a monoclonal antibody against tumour necrosis factor alpha. AIM In the first randomised placebo controlled trial of any drug for the treatment of PG, we have studied the role of inflixi...